2017 Conference Program

Press Conference

Wednesday, September 6, 2017  

10:45 am - 11:00 am


11:00 am - 12:30 pm

Session 1: Neoantigens

Ton Schumacher, The Netherlands Cancer Institute
T-cell recognition in human cancer

Ugur Sahin, BioNTech, TRON Translational Oncology
Individualized cancer immunotherapy - exploring a new landscape

Stephen Schoenberger, La Jolla Institute
An HLA-agnostic functional neoantigen discovery platform

Lunch                                                                         12:30 pm - 1:30 pm

Session 1: Neoantigens continued                          1:30 pm - 3:30 pm

Catherine Wu, Dana-Farber Cancer Institute/ Harvard Medical School
Building personal cancer vaccines

Sine Reker Hadrup, Technical University of Denmark
Detection of neoepitope reactive T-cells based on personalized mutational landscapes

Timothy Chan, Memorial Sloan Kettering Cancer Center
How cancer genomes shape immunotherapy response

Céline Laumont, Université de Montréal
Identification of non-exonic immunogenic targets for cancer immunotherapy using
a novel proteogenomic approach*

Vinod Balachandran, Memorial Sloan Kettering Cancer Center
Identification of unique neoantigen qualities in long-term pancreatic cancer survivors*

*Proferred presentation

Refreshment Break                                                    3:30 pm - 4:00pm

 4:00 pm - 6:00 pm

Session 2: Novel mechanisms of immunosuppression and immune evasion

Nicholas Restifo, National Cancer Institute
Essential genes for cancer immunotherapy

Padmanee Sharma, The University of Texas MD Anderson Cancer Center
From the clinic to the lab: Investigating response and resistance mechanisms to immune checkpoint therapy

Jesse Zaretsky, UCLA Medical Center
Mechanisms of acquired resistance to anti-PD1 immunotherapy in melanoma

Marian Burr, Peter MacCallum Cancer Centre
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity*

Yumeng Mao, AstraZeneca iMed Oncology
Evaluation of the functional role of TAM kinases in tumour-driven immune suppression*

*Proferred presentation

6:00 pm - 8:00 pm

Reception and Poster Session A

The following topics will be presented:

Neoantigens and Cancer Mutations
Oncolytic Viruses
Adoptive Cell Therapy
Checkpoint Blockade Therapy
Immunomonitoring and Biomarkers
Cancer-Mediated Immunosuppression

Thursday, September 7, 2017

8:00 am - 9:00 am

William B. Coley Lecture

Thomas F. Gajewski, The University of Chicago
From the tumor microenvironment to effective immunotherapies

Refreshment Break                                                   9:00 am - 9:30 am

Session 3: Tissue biomarkers predicting                9:30 am - 11:30 am
response to therapy 

Thomas Tüting, University Hospital Magdeburg
The role of neutrophils in cancer immunotherapy

Drew Pardoll, Johns Hopkins University
Dissection of T-cell repertoire and function in lung cancer

Wolf Hervé Fridman, Cordeliers Research Centre, University Paris - Descartes
Deleterious immune contextures in cancer

Belinda Palermo, Regina Elena National Cancer Institute
An oligoclonal gp100-specific TCR repertoire of high avid, polyfunctional and
tumor-reactive CD8+ T-cell clones, identified in melanoma patients
treated with chemoimmunotherapy*

Niels Halama, German Cancer Research Center (DKFZ)
Spatial co-expression of immunomarkers at the cellular level in
sequential sections of hepatic colorectal metastases*

*Proferred presentation

Lunch                                                                          11:30 pm - 1:00 pm

1:00 pm - 3:00 pm

Session 4: Novel agents

Ignacio Melero, Universidad de Navarra
Building combined immunotherapies on CD137 and PD-1 foundations

Özlem Türeci, Ci3-Cluster for Individualized Immune Intervention
IMAB362 - A novel immune - effector activating mAB for the treatment of solid cancers

Patrick Baeuerle, TCR² Therapeutics Inc.
TRuC - T-cells targeting CD19 or mesothelin demonstrate superior antitumor activity in
preclinical models compared to CAR-T-cells

Ulrike Schindler, Arcus Biosciences
Novel small-molecule inhibitors of ecto-nucleotidase CD73 promote activation of
human CD4+ and CD8+ T-cells and have profound effects in experimental tumor models*

Nicholas Huntington, The Walter and Eliza Hall Institute (WEHI)
CIS checkpoint inhibition synergizes with activating receptors and impairs
inhibitory/suppressive pathways in NK cells resulting in superior tumor immunity

*Proferred presentation


Refreshment Break                                                   3:00 pm - 3:30 pm

3:30 pm - 6:00 pm

Session 5: Adoptive cell therapies

Hyam Levitsky, Juno Therapeutics
Building the tools to extend the benefit of genetically modified T-cell therapies for cancer

Dirk Busch, Technical University Munich
Choice of optimal T cell subsets and implementation of safeguards for adoptive T-cell therapy

Michael Jensen, University of Washington, School of Medicine, Department of Pediatrics
Next steps for iteration of CD19CAR therapy to definitive curative therapy

Cedrik M. Britten, GlaxoSmithKline
Engineered T cells – simple and not so simple living machines as the best medicines for cancer

Anja Feldmann, Helmholtz-Zentrum Dresden-Rossendorf (HZDR)
Redirection of human T lymphocytes armed with on/off switchable universal
chimeric antigen receptors against various malignant cells*

Andrew G. Sikora, Baylor College of Medicine
TGF beta 1- reprogrammed myeloid-derived suppressor cells lose
immunosuppressive function and acquire Fas-dependent tumor killing activity*

*Proferred presentation

FRIDAY, September 8, 2017

8:00 am - 10:00 am

Session 6:  Combination therapies

Ira Mellman, Genentech
The mechanistic basis of cancer immunotheraphy

Sjoerd van der Burg, Leiden University Medical Center
Myeloid cell modulating chemotherapy and therapeutic vaccination for treatment of HPV - driven cancer

Michael Curran, The University of Texas MD Anderson Cancer Center
Hypoxia reduction sensitizes solid tumors to T cell checkpoint immunotherapy

Liang Deng, Memorial Sloan Kettering Cancer Center
The combination of intratumoral injection of inactivated MVA and systemic delivery of immune
checkpoint blockade leads to eradication of large established tumors and distant tumors*

Partha Sarathi Chowdhury, Kyoto University
Synergistic effect of mitochondrial activation and PD-1 blockade in boosting antitumor immunity*

*Proferred presentation

Refreshment Break                                                  10:00 am - 10:30 am

10:30 am - 12:30 pm

Session 7:  Novel approaches for checkpoint blockade failure

George Coukos, Ludwig Institute for Cancer Research
Spontaneous and vaccine-induced immune response against ovarian cancer includes high-avidity T cells against tumor neo-epitopes

Alexander Rudensky, Memorial Sloan Kettering Cancer Center
Regulatory T-cell function in health and disease

Sergio Quezada, University College London Cancer Institute
Targeting immune regulation at the tumor site

Simon Heidegger, Technical University Munich
Tumor-intrinsic RIG-I signaling promotes anti-CTLA-4 checkpoint inhibitor-mediated anticancer immunity*

Matthias Kloor, Heidelberg University
High density of PD-1-positive T-cells are associated with immune evasion in DNA mismatch repair deficient colorectal cancers*

*Proferred presentation

Lunch                                                                        12:30 pm - 2:00 pm

Session 8:   Other checkpoint blocking and          2:00 pm - 3:45 pm
immunomodulating antibodies

Charles Drake, Columbia University Medical Center
Treg depletion as a foundation for combinatorial immunotherapy

Ana Anderson, Harvard Medical School
Regulation of the CD8+ T-cell response in cancer

Martin Glennie, University of Southampton
Developing immunostimulatory abs to promote innate and acquired cancer immunity
Proffered presentation to be selected from submitted abstracts 

Ofer Levy, Compugen Ltd.
Computational discovery and experimental validation of CGEN-15032 as a novel target
for cancer immunotherapy

*Proferred presentation      

Refreshment Break                                                   3:45 pm - 4:15 pm

Session 9:  Microbiota                                               4:15 pm - 5:30 pm

Laurence Zitvogel, Gustave Roussy Cancer Institute
Intestinal microbiota shaping the anticancer immune response

Giorgio Trinchieri, National Institutes of Health
Cancer as a disease of the symbiont/ metaorganism

Eleonora Cremonesi, University Hospital and University of Basel
Gut microbiota modulate T-cell trafficking into human colorectal cancer*

*Proferred presentation                                 

Keynote Lecture                                                         5:30 pm - 6:15 pm

Alberto Mantovani, Istituto Clinico Humanitas, Humanitas University
The yin - yang of innate immunity, inflammation and cancer

Reception and Poster Session B                             6:30 pm - 8:30 pm

The following topics will be presented:                 

Cancer Vaccines and Targets
Combination Therapies
New Agents and Their Mode of Action
Clinical Trials of Cancer Immunotherapies
Tumor Microenvironment and Its Modulation

Saturday, September 9, 2017

8:00 am - 10:00 am

Session 10: Therapy against hostile elements in the cancer microenvironment

Dmitry Gabrilovich, The Wistar Institute
Therapeutic regulation of myeloid - derived suppressor cells

Serge Fuchs, University of Pennsylvania
Inactivation of type I interferon signaling in tumor microenvironment: therapeutic implications

Yousef Zahkaria, University of Iowa
Combined inhibition of the IDO and PD-1 pathways improves the response rate for patients with advanced melanoma

Alex Yee-Chen Huang, Case Western Reserve University School of Medicine
Disrupting signaling between ectopic osteosarcoma-associated VCAM-1 and α4β1 integrin in macrophages ameliorates pulmonary metastasis*

Roberta Melchionna, Regina Elena National Cancer Institute
The role of hMENA-related splicing in the cross/talk between
cancer cells and CAFs in PDAC and NSCLC*

*Proferred presentation

Refreshment Break                                                   10:00 am - 10:30 am

10:30 am - 12:15 pm

Session 11: Oncolytic viruses

John Bell, Ottawa Hospital Research Institute
Replicating viruses as biological machines to treat cancer

Pedro Beltran, Amgen Inc.
Mechanisms of action of talimogene laherparepvec: From bench to bedside

Stephen J. Russell, Mayo Clinic
Oncolytic viruses as antigen agnostic vaccines

Tala Shekarian, Leon Berard Cancer Research Center
Immunostimulatory and oncolytic properties of rotavirus can overcome
resistance to immune checkpoint blockade therapy*

*Proferred presentation

The Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, Mainz, Germany, 06/09/2017-09/09/2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 22 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.